Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119474482> ?p ?o ?g. }
- W3119474482 endingPage "276" @default.
- W3119474482 startingPage "266" @default.
- W3119474482 abstract "Benzbromarone (BBR), a potent uricosuric agent for the management of gout, is known to cause fatal fulminant hepatitis. Although the mechanism of BBR-induced idiosyncratic hepatotoxicity remains unelucidated, cytochrome P450 enzyme–mediated bioactivation of BBR to electrophilic reactive metabolites is commonly regarded as a key molecular initiating event. However, apart from causing aberrant toxicities, reactive metabolites may result in mechanism-based inactivation (MBI) of cytochrome P450. Here, we investigated and confirmed that BBR inactivated CYP3A4 in a time-, concentration-, and NADPH-dependent manner with <i>K</i><sub>I</sub>, <i>k</i><sub>inact</sub>, and partition ratio of 11.61 µM, 0.10 minutes<sup>−1</sup>, and 110, respectively. Coincubation with ketoconazole, a competitive inhibitor of CYP3A4, attenuated the MBI of CYP3A4 by BBR, whereas the presence of glutathione and catalase did not confer such protection. The lack of substantial recovery of enzyme activity postdialysis and after oxidation with potassium ferricyanide, combined with the absence of a Soret peak in spectral difference scans, implied that MBI of CYP3A4 by BBR did not occur through the formation of quasi-irreversible metabolite-intermediate complexes. Analysis of the reduced CO-difference spectrum revealed an ∼44% reduction in ferrous-CO binding and hinted that inactivation is mediated via irreversible covalent adduction to both the prosthetic heme moiety and the apoprotein. Finally, our in silico covalent docking analysis further suggested the modulation of substrate binding to CYP3A4 via the covalent adduction of epoxide-derived reactive intermediates of BBR to two key cysteine residues (Cys239 and Cys58) vicinal to the entrance of the orthosteric binding site. <h3>SIGNIFICANCE STATEMENT</h3> Although the bioactivation of benzbromarone (BBR) to reactive metabolites has been well characterized, its potential to cause mechanism-based inactivation (MBI) of cytochrome P450 has not been fully investigated. This study reports the MBI of CYP3A4 by BBR via irreversible covalent adduction and develops a unique covalent docking methodology to predict the structural molecular determinants underpinning the inactivation for the first time. These findings lay the groundwork for future investigation of clinically relevant drug-drug interactions implicating BBR and mechanisms of BBR-induced idiosyncratic hepatotoxicity." @default.
- W3119474482 created "2021-01-18" @default.
- W3119474482 creator A5011057255 @default.
- W3119474482 creator A5015267577 @default.
- W3119474482 creator A5020068139 @default.
- W3119474482 creator A5036209169 @default.
- W3119474482 date "2021-01-12" @default.
- W3119474482 modified "2023-10-17" @default.
- W3119474482 title "Mechanism-Based Inactivation of Cytochrome P450 3A4 by Benzbromarone" @default.
- W3119474482 cites W1550877969 @default.
- W3119474482 cites W1741338572 @default.
- W3119474482 cites W1951469402 @default.
- W3119474482 cites W1984464701 @default.
- W3119474482 cites W1985588649 @default.
- W3119474482 cites W1989145752 @default.
- W3119474482 cites W1995089209 @default.
- W3119474482 cites W1995770177 @default.
- W3119474482 cites W1999119308 @default.
- W3119474482 cites W2007615684 @default.
- W3119474482 cites W2010427019 @default.
- W3119474482 cites W2030455156 @default.
- W3119474482 cites W2036508585 @default.
- W3119474482 cites W2053703752 @default.
- W3119474482 cites W2058701275 @default.
- W3119474482 cites W2063855838 @default.
- W3119474482 cites W2064931754 @default.
- W3119474482 cites W2068780263 @default.
- W3119474482 cites W2072667467 @default.
- W3119474482 cites W2078780740 @default.
- W3119474482 cites W2099242535 @default.
- W3119474482 cites W2104281379 @default.
- W3119474482 cites W2106195907 @default.
- W3119474482 cites W2109313097 @default.
- W3119474482 cites W2110935327 @default.
- W3119474482 cites W2117131053 @default.
- W3119474482 cites W2124039416 @default.
- W3119474482 cites W2130983257 @default.
- W3119474482 cites W2136933657 @default.
- W3119474482 cites W2140640244 @default.
- W3119474482 cites W2140839856 @default.
- W3119474482 cites W2144738033 @default.
- W3119474482 cites W2146402650 @default.
- W3119474482 cites W2146989631 @default.
- W3119474482 cites W2149786401 @default.
- W3119474482 cites W2152964734 @default.
- W3119474482 cites W2157122545 @default.
- W3119474482 cites W2163335277 @default.
- W3119474482 cites W2171243007 @default.
- W3119474482 cites W2172544261 @default.
- W3119474482 cites W2216830726 @default.
- W3119474482 cites W2254591010 @default.
- W3119474482 cites W2314083131 @default.
- W3119474482 cites W2495611317 @default.
- W3119474482 cites W2497469014 @default.
- W3119474482 cites W2571511441 @default.
- W3119474482 cites W2794725602 @default.
- W3119474482 cites W2899070097 @default.
- W3119474482 cites W2916087834 @default.
- W3119474482 cites W2971358898 @default.
- W3119474482 cites W4248725772 @default.
- W3119474482 doi "https://doi.org/10.1124/molpharm.120.000086" @default.
- W3119474482 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33436520" @default.
- W3119474482 hasPublicationYear "2021" @default.
- W3119474482 type Work @default.
- W3119474482 sameAs 3119474482 @default.
- W3119474482 citedByCount "12" @default.
- W3119474482 countsByYear W31194744822021 @default.
- W3119474482 countsByYear W31194744822022 @default.
- W3119474482 countsByYear W31194744822023 @default.
- W3119474482 crossrefType "journal-article" @default.
- W3119474482 hasAuthorship W3119474482A5011057255 @default.
- W3119474482 hasAuthorship W3119474482A5015267577 @default.
- W3119474482 hasAuthorship W3119474482A5020068139 @default.
- W3119474482 hasAuthorship W3119474482A5036209169 @default.
- W3119474482 hasBestOaLocation W31194744821 @default.
- W3119474482 hasConcept C109650736 @default.
- W3119474482 hasConcept C161790260 @default.
- W3119474482 hasConcept C181199279 @default.
- W3119474482 hasConcept C185592680 @default.
- W3119474482 hasConcept C192937433 @default.
- W3119474482 hasConcept C2776217839 @default.
- W3119474482 hasConcept C2777477808 @default.
- W3119474482 hasConcept C2777601384 @default.
- W3119474482 hasConcept C2779721657 @default.
- W3119474482 hasConcept C2779881121 @default.
- W3119474482 hasConcept C2780274859 @default.
- W3119474482 hasConcept C526171541 @default.
- W3119474482 hasConcept C538909803 @default.
- W3119474482 hasConcept C55493867 @default.
- W3119474482 hasConcept C71240020 @default.
- W3119474482 hasConceptScore W3119474482C109650736 @default.
- W3119474482 hasConceptScore W3119474482C161790260 @default.
- W3119474482 hasConceptScore W3119474482C181199279 @default.
- W3119474482 hasConceptScore W3119474482C185592680 @default.
- W3119474482 hasConceptScore W3119474482C192937433 @default.
- W3119474482 hasConceptScore W3119474482C2776217839 @default.
- W3119474482 hasConceptScore W3119474482C2777477808 @default.
- W3119474482 hasConceptScore W3119474482C2777601384 @default.